Lachlan Hanbury-Brown
Analyst
William Blair
Equibles does not estimate personal net worth.
About Lachlan Hanbury-Brown
Lachlan Hanbury-Brown is recorded as Analyst at William Blair. Lachlan Hanbury-Brown has spoken on 16 earnings calls and 1 other investor event across 8 companies, most recently for Ultragenyx Pharmaceutical Inc. on November 3, 2026. Those appearances were for Tarsus Pharmaceuticals, Inc. (TARS), ARS Pharmaceuticals, Inc. (SPRY), Harrow, Inc. (HROW), Zevra Therapeutics, Inc. (ZVRA), Ultragenyx Pharmaceutical Inc. (RARE) and 3 other companies. The companies whose calls Lachlan Hanbury-Brown spoke on are classified in the Healthcare sector.
Lachlan Hanbury-Brown on recent calls
“I wanted to follow up on the point about the urgency to treat with FAY-UV and sort of wondering how you're seeing that play out so far.”
“I think the strong growth in what's normally a seasonally slower quarter was pretty notable.”
“So, Don, you've talked about sort of focusing on the prescriber engagement. The obvious outcome of that is sort of scripts and revenue, but I'm wondering if there are other metrics that you can look at in the interim.”
“I appreciate that's obviously somewhat dependent on the exact timing of the close, but should we just be thinking about sort of pro-rathering what you said about 27 for 26?”
Affiliation history
-
William Blair
Analyst
Source not stated
Current
Company network
HROW
Drug Manufacturers - Specialty & Generic · Healthcare
Apellis Pharmaceuticals, Inc.
Biotechnology · Healthcare
Recent activity
Show 5 earlier activities
-
-
Earnings call
Apellis Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Apellis Pharmaceuticals, Inc.
-
-
-